echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Lancet sub-journal: Antibiotic use or directly associated with an increased risk of inflammatory bowel disease in individuals.

    Lancet sub-journal: Antibiotic use or directly associated with an increased risk of inflammatory bowel disease in individuals.

    • Last Update: 2020-09-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    19, 2020 // -- In a recent study published in the international journal The Lancet Gastroenterology and Hepatology, scientists from the Caroline Institute in Sweden and other institutions found that the use of antibiotics (especially more widely available antibiotics, broad-spectrum antibiotics) or increased risk of new inflammatory bowel disease (IBD) and its subtypes of ulcerative colitis and crohn's disease in the population was directly related.
    when researchers compared patients with their siblings, the relationship between antibiotic therapy and their IBD may still exist.
    Photo Source: Wikipedia/CC BY-SA 3.0 Today, IBD is becoming more common around the world, especially in countries such as Europe and the United States, as these regions are experiencing rapid economic growth, changing hygiene conditions and more frequent use of antibiotics;
    In this large study that analyzed the link between antibiotic therapy and IBD risk, the researchers made it clear that frequent use of antibiotics is directly related to individuals with IBD, ulcerative colitis, and Crohn's disease;
    , however, despite this compelling theoretical basis and seemingly more intuitive assumptions, researchers have not yet conducted population-scale survey analysis to support this hypothesis.
    the study, researchers identified about 24,000 IBD patients ,including 16,000 with ulcerative colitis and 8,000 with Crohn's disease , and compared them to 28,000 siblings and 117,000 A comparative analysis of the general population showed that when multiple risk factors were adjusted, previous antibiotic use nearly tripled the risk of IBD in individuals, and the risk of ulcerative colitis and Crohn's disease increased, with a higher risk of developing broad-spectrum antibiotics.
    According to the researchers, early research in the field was small and rarely followed up for more than a few years, contrary to previous studies, in which researchers registered and analyzed all eligible new IBD patients on a population-based basis over a 10-year study period, while limiting selective bias; Professor Ludvigsson said the wide coverage of drugs in Sweden and the fact that information on almost all drugs, including antibiotics, was almost complete, which minimized the bias in the identification of studies and made Sweden an ideal place to study IBD risk factors.
    IBD affects the health of about 1% of the Swedish population, but also has a substantial impact on the quality of life of patients, but also related to the increased risk of death and cancer, the researchers said, identifying IBD risk factors for effective prevention and treatment of the disease is very important, in this study researchers revealed the link between antibiotic use and increased risk of IBD, later or for the development of new strategies to intervene in the occurrence and development of IBD provides a certain research basis and thinking.
    () Original source: Long H Nguyen, Anne Körtqvist, Yin Cao, et al. Antibiotic use and the development of the agency bowel disease: a national case/control study in Sweden, The Lancet Gastroenterology and Hepatology, online Aug. 17, 2020, DOI: 10.1016/S2468-1253 (20) 30267-3.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.